Tus-Pharmaceutical Group Co., Ltd. (SHE:000590)

Tus-Pharmaceutical Group Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	216.54	177.29	189.77	235.42	250.68	342.95
Trading Asset Securities	-	-	-	25.11	75.15	-
Cash & Short-Term Investments	216.54	177.29	189.77	260.53	325.83	342.95
Cash Growth	7.91%	-6.58%	-27.16%	-20.04%	-4.99%	9.10%
Accounts Receivable	96.58	103.15	154.4	117.16	124.81	111.22
Other Receivables	34.23	90.28	60.51	30.11	6	1.82
Receivables	130.8	193.43	214.91	147.27	130.82	113.04
Inventory	128.64	124.78	130.09	118.22	86.59	50.82
Prepaid Expenses	-	2.32	-	0.03	0	0.57
Other Current Assets	18.65	2.17	4.79	3.06	10.65	1.23
Total Current Assets	494.63	499.99	539.55	529.11	553.88	508.62
Property, Plant & Equipment	310.72	312.66	293.81	289.75	240.89	224.73
Long-Term Investments	3.6	20.03	20.9	19	19	-
Goodwill	13.2	13.2	131.64	137.14	-	-
Other Intangible Assets	127.77	131.06	132.33	157.44	133.69	138.16
Long-Term Accounts Receivable	-	3.09	5.05	7.42	-	-
Long-Term Deferred Tax Assets	11.73	8.18	4.09	5.23	4.97	4.56
Long-Term Deferred Charges	6.7	6.29	3.32	2.93	1.82	1.84
Other Long-Term Assets	40.85	18.92	20.42	19	13.57	14.25
Total Assets	1,009	1,013	1,151	1,167	967.83	892.16
Accounts Payable	76.21	73.24	83.55	64.01	41.67	38.62
Accrued Expenses	17.87	43.88	46.62	50.8	40.37	33.29
Short-Term Debt	30	0.75	-	25.82	-	5
Current Portion of Long-Term Debt	7.5	11.01	10	10.1	-	-
Current Portion of Leases	-	2.94	2.36	2.69	3	-
Current Income Taxes Payable	1.92	6.8	2.3	3.4	3.85	3.99
Current Unearned Revenue	50.2	45.33	50.12	56.13	53.42	26.35
Other Current Liabilities	49.72	52.31	53.82	58.45	44.68	53.76
Total Current Liabilities	233.42	236.26	248.77	271.42	186.98	161.02
Long-Term Debt	95.05	82.22	80	90	-	-
Long-Term Leases	1.56	1.49	3.07	5.18	5.59	-
Long-Term Unearned Revenue	45.25	43.99	42.44	44.37	46.29	41.57
Long-Term Deferred Tax Liabilities	4.91	5.15	5.91	7.47	0.02	-
Other Long-Term Liabilities	45.04	43.07	42.72	46.09	46.62	44.69
Total Liabilities	425.23	412.18	422.92	464.53	285.5	247.27
Common Stock	239.47	239.47	239.47	239.47	239.47	239.47
Additional Paid-In Capital	474.06	474.06	474.06	474.06	474.06	474.06
Retained Earnings	-132.46	-115.29	10.18	-15.06	-33.21	-68.65
Total Common Equity	581.08	598.25	723.72	698.47	680.32	644.88
Minority Interest	2.89	2.99	4.49	4.03	2	-
Shareholders' Equity	583.97	601.23	728.2	702.5	682.32	644.88
Total Liabilities & Equity	1,009	1,013	1,151	1,167	967.83	892.16
Total Debt	134.12	98.42	95.43	133.79	8.58	5
Net Cash (Debt)	82.42	78.87	94.34	126.74	317.24	337.95
Net Cash Growth	-21.21%	-16.40%	-25.56%	-60.05%	-6.13%	7.51%
Net Cash Per Share	0.34	0.33	0.39	0.53	1.32	1.41
Filing Date Shares Outstanding	239.53	239.47	239.47	239.47	239.47	239.47
Total Common Shares Outstanding	239.53	239.47	239.47	239.47	239.47	239.47
Working Capital	261.22	263.73	290.78	257.69	366.9	347.6
Book Value Per Share	2.43	2.50	3.02	2.92	2.84	2.69
Tangible Book Value	440.1	453.98	459.75	403.89	546.63	506.72
Tangible Book Value Per Share	1.84	1.90	1.92	1.69	2.28	2.12
Buildings	-	267.95	247.28	243.93	198.81	145.94
Machinery	-	220.21	197.31	189.09	174.95	137.89
Construction In Progress	-	8.81	23.83	15.21	4.18	79.44

Source: S&P Global Market Intelligence. Standard template. Financial Sources.